New insights into the inter-organ crosstalk mediated by ChREBP
Carbohydrate response element binding protein (ChREBP) is a glucose responsive transcription factor recognized by its critical role in the transcriptional control of glycolysis and de novo lipogenesis. Substantial advances in the field have revealed novel ChREBP functions. Indeed, due to its actions in different tissues, ChREBP modulates the inter-organ communication through secretion of peptides and lipid factors, ensuring metabolic homeostasis. Dysregulation of these orchestrated interactions is associated with development of metabolic diseases such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). Here, we recapitulate the current knowledge about ChREBP-mediated inter-organ crosstalk through secreted factors and its physiological implications. As the liver is considered a crucial endocrine organ, we will focus in this review on the role of ChREBP-regulated hepatokines. Lastly, we will discuss the involvement of ChREBP in the progression of metabolic pathologies, as well as how the impairment of ChREBP-dependent signaling factors contributes to the onset of such diseases..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Frontiers in Endocrinology - 14(2023) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thais Carbinatti [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
ChREBP |
|---|
| doi: |
10.3389/fendo.2023.1095440 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ079816991 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ079816991 | ||
| 003 | DE-627 | ||
| 005 | 20230410112957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230310s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fendo.2023.1095440 |2 doi | |
| 035 | |a (DE-627)DOAJ079816991 | ||
| 035 | |a (DE-599)DOAJ649f7fb803eb4a97b3d6317931b977e6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Thais Carbinatti |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New insights into the inter-organ crosstalk mediated by ChREBP |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Carbohydrate response element binding protein (ChREBP) is a glucose responsive transcription factor recognized by its critical role in the transcriptional control of glycolysis and de novo lipogenesis. Substantial advances in the field have revealed novel ChREBP functions. Indeed, due to its actions in different tissues, ChREBP modulates the inter-organ communication through secretion of peptides and lipid factors, ensuring metabolic homeostasis. Dysregulation of these orchestrated interactions is associated with development of metabolic diseases such as type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). Here, we recapitulate the current knowledge about ChREBP-mediated inter-organ crosstalk through secreted factors and its physiological implications. As the liver is considered a crucial endocrine organ, we will focus in this review on the role of ChREBP-regulated hepatokines. Lastly, we will discuss the involvement of ChREBP in the progression of metabolic pathologies, as well as how the impairment of ChREBP-dependent signaling factors contributes to the onset of such diseases. | ||
| 650 | 4 | |a ChREBP | |
| 650 | 4 | |a inter-organ crosstalk | |
| 650 | 4 | |a metabolism | |
| 650 | 4 | |a hepatokines | |
| 650 | 4 | |a metabolic diseases | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Marion Régnier |e verfasserin |4 aut | |
| 700 | 0 | |a Lucia Parlati |e verfasserin |4 aut | |
| 700 | 0 | |a Fadila Benhamed |e verfasserin |4 aut | |
| 700 | 0 | |a Catherine Postic |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Endocrinology |d Frontiers Media S.A., 2011 |g 14(2023) |w (DE-627)DOAJ000043443 |x 16642392 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fendo.2023.1095440 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/649f7fb803eb4a97b3d6317931b977e6 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/articles/10.3389/fendo.2023.1095440/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1664-2392 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 | ||